The story
Lithuania’s medical reform, effective from May 2019, opened a route for registered cannabis-based medicines. Patients would receive pharmaceutical products whose safety and effectiveness had been demonstrated, under rules separate from the prohibition on recreational possession.[1][2]
A parliamentary route to medicines
Parliament approved the reform on 11 October 2018, with ninety members voting in favour and three abstaining.[1] Conservative politicians Mykolas Majauskas and Irena Degutienė had promoted the proposal, and the vote sent it to the president ahead of a planned 1 May start.[1]
Majauskas presented the change as a way for seriously ill patients to obtain medicines registered in the European Union, for treatment or symptom relief.[1] That placed the medicine and its authorisation at the centre of access: a diagnosis alone would not create an open market in cannabis.[1]
What the medicines register shows
The state register lists Epidyolex, a prescription oral solution containing cannabidiol at 100 mg per millilitre.[3] Its authorisation date is 19 September 2019, through the central European procedure.[3]
The register distinguishes being authorised from being supplied: one 100 ml bottle presentation is marked as supplied, while the three-bottle presentation is not.[3] It also marks this cannabidiol medicine as not controlled.[3] A patient’s actual route therefore depends on the particular product and package available through the medicines system.[3]
Manufacturers need separate permissions
The medicines agency provides a licensing route for manufacturing medicinal products containing Schedule I substances.[4] Applicants need both a pharmaceutical manufacturing licence and a licence for the controlled-substance activity.[4]
Those requirements regulate the businesses making medicines; they do not give individual patients a cultivation permit.[4] The agency’s licensing guidance keeps manufacturing, wholesale and other controlled activities within defined authorisations.[4]
Recreational reform followed another path
The drug-control department records that from January 2017, small unauthorised possession was handled as a criminal misdemeanour, replacing overlapping administrative and criminal liability.[2] The medical route developed alongside that criminal law.[1][2]
In April 2025, a parliamentary committee returned to the stalled proposal for administrative treatment of small cannabis possession.[5] Lithuania’s country profile tracks that debate separately from the registered-medicine route patients can use.[3][5]
Score by segment 0 to 10
- Possession · 25%1 → 1
- Personal cultivation · 25%2 → 2
- Punishment & enforcement · 20%2 → 2
- Sharing & gifting · 10%1 → 1
- Consumption · 10%1 → 1
- Legal access · 10%0 → 1+1
The bar shows the score after the change; the tick marks where it stood before. The scores after the change are Lithuania's current scores.
References
- LRT — Parliament approves cannabis medicines, 11 October 2018archived
- Lithuania Drug, Tobacco and Alcohol Control Department — National drug lawsarchived
- Lithuanian State Medicines Control Agency — Epidyolex registration and supplyarchived
- Lithuanian State Medicines Control Agency — Controlled-substance manufacturing licencesarchived
- BNS via Made in Vilnius — Committee revisits cannabis reform, 7 April 2025archived
Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.